Olivier Vandenplas1, Denis Vinnikov2, Paul D Blanc3, Ioana Agache4, Claus Bachert5, Michael Bewick6, Lars-Olaf Cardell7, Paul Cullinan8, Pascal Demoly9, Alexis Descatha10, Joao Fonseca11, Tari Haahtela12, Peter W Hellings13, Jacques Jamart14, Juha Jantunen15, Ömer Kalayci16, David Price17, Boleslaw Samolinski18, Joaquin Sastre19, Longxiu Tian20, Antonio L Valero21, Xinyi Zhang22, Jean Bousquet23. 1. Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. Electronic address: olivier.vandenplas@uclouvain.be. 2. Department of Biostatistics and Evidence-Based Medicine, Al-Farabi Kazakh National University, Almaty, Kazakhstan. 3. Division of Occupational and Environmental Medicine, Department of Medicine, University of California San Francisco, San Francisco, Calif. 4. Faculty of Medicine, Transylvania University, Brasov, Romania. 5. Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium. 6. iQ4U Consultants Ltd, London, UK. 7. Department of Ear, Nose and Throat Diseases, Karolinska University Hospital, Stockholm, Sweden. 8. Department of Occupational and Environmental Medicine, Royal Brompton Hospital and Imperial College (NHLI), London, UK. 9. Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France. 10. AP-HP, Occupational Health Department, Unité de pathologie professionnelle, University Hospital of West Suburb of Paris, Poincaré, Garches, and Versailles St-Quentin University, INSERM, Villejuif, France. 11. Center for Health Technology and Services Research-CINTESIS, Faculdade de Medicina, Universidade do Porto; and Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal. 12. Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. 13. Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium. 14. Scientific Support Unit, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 15. South Karelia Allergy and Environment Institute, Imatra, Finland. 16. Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey. 17. Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, UK; Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK. 18. Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland. 19. Allergy Department, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, CIBER de Enfermedades Respiratorias (CIBERES), Institute Carlos III, Madrid, Spain. 20. Ross School of Business, University of Michigan, Ann Arbor, Mich. 21. Pneumology and Allergy Department Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain. 22. Renmin University, Beijing, China. 23. MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France; INSERM, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, U1168, Paris, France; UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France.
Abstract
BACKGROUND: Allergic rhinitis (AR) is increasingly acknowledged as having a substantial socioeconomic impact associated with impaired work productivity, although available information remains fragmented. OBJECTIVE: This systematic review summarizes recently available information to provide a quantitative estimate of the burden of AR on work productivity including lost work time (ie, absenteeism) and reduced performance while working (ie, presenteeism). METHODS: A Medline search retrieved original studies from 2005 to 2015 pertaining to the impact of AR on work productivity. A pooled analysis of results was carried out with studies reporting data collected through the validated Work Productivity and Activity Impairment (WPAI) questionnaire. RESULTS: The search identified 19 observational surveys and 9 interventional studies. Six studies reported economic evaluations. Pooled analysis of WPAI-based studies found an estimated 3.6% (95% confidence interval [CI], 2.4; 4.8%) missed work time and 35.9% (95% CI, 29.7; 42.1%) had impairment in at-work performance due to AR. Economic evaluations indicated that indirect costs associated with lost work productivity are the principal contributor to the total AR costs and result mainly from impaired presenteeism. The severity of AR symptoms was the most consistent disease-related factor associated with a greater impact of AR on work productivity, although ocular symptoms and sleep disturbances may independently affect work productivity. Overall, the pharmacologic treatment of AR showed a beneficial effect on work productivity. CONCLUSIONS: This systematic review provides summary estimates of the magnitude of work productivity impairment due to AR and identifies its main determinant factors. This information may help guide both clinicians and health policy makers.
BACKGROUND:Allergic rhinitis (AR) is increasingly acknowledged as having a substantial socioeconomic impact associated with impaired work productivity, although available information remains fragmented. OBJECTIVE: This systematic review summarizes recently available information to provide a quantitative estimate of the burden of AR on work productivity including lost work time (ie, absenteeism) and reduced performance while working (ie, presenteeism). METHODS: A Medline search retrieved original studies from 2005 to 2015 pertaining to the impact of AR on work productivity. A pooled analysis of results was carried out with studies reporting data collected through the validated Work Productivity and Activity Impairment (WPAI) questionnaire. RESULTS: The search identified 19 observational surveys and 9 interventional studies. Six studies reported economic evaluations. Pooled analysis of WPAI-based studies found an estimated 3.6% (95% confidence interval [CI], 2.4; 4.8%) missed work time and 35.9% (95% CI, 29.7; 42.1%) had impairment in at-work performance due to AR. Economic evaluations indicated that indirect costs associated with lost work productivity are the principal contributor to the total AR costs and result mainly from impaired presenteeism. The severity of AR symptoms was the most consistent disease-related factor associated with a greater impact of AR on work productivity, although ocular symptoms and sleep disturbances may independently affect work productivity. Overall, the pharmacologic treatment of AR showed a beneficial effect on work productivity. CONCLUSIONS: This systematic review provides summary estimates of the magnitude of work productivity impairment due to AR and identifies its main determinant factors. This information may help guide both clinicians and health policy makers.
Authors: Jordan R Kuiper; Annemarie G Hirsch; Karen Bandeen-Roche; Agnes S Sundaresan; Bruce K Tan; Robert C Kern; Robert P Schleimer; Brian S Schwartz Journal: J Occup Environ Med Date: 2019-08 Impact factor: 2.162
Authors: J Bousquet; A Bedbrook; W Czarlewski; G L Onorato; S Arnavielhe; D Laune; E Mathieu-Dupas; J Fonseca; E Costa; O Lourenço; M Morais-Almeida; A Todo-Bom; M Illario; E Menditto; G W Canonica; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; W J Fokkens; N H Chavannes; S Reitsma; A A Cruz; J da Silva; F S Serpa; D Larenas-Linnemann; J M Fuentes Perez; Y R Huerta-Villalobos; D Rivero-Yeverino; E Rodriguez-Zagal; A Valiulis; R Dubakiene; R Emuzyte; V Kvedariene; I Annesi-Maesano; H Blain; P Bonniaud; I Bosse; Y Dauvilliers; P Devillier; J F Fontaine; J L Pépin; N Pham-Thi; F Portejoie; R Picard; N Roche; C Rolland; P Schmidt-Grendelmeier; P Kuna; B Samolinski; J M Anto; V Cardona; J Mullol; H Pinnock; D Ryan; A Sheikh; S Walker; S Williams; S Becker; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P V Tomazic; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; T Vasankari; B Gemicioğlu; A Yorgancioglu; N G Papadopoulos; E P Prokopakis; I G Tsiligianni; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; M E Zernotti; I Kull; E Melén; M Wickman; C Bachert; P W Hellings; G Brusselle; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; L P Boulet; J Bouchard; D K Chu; H J Schünemann; M Sova; G De Vries; M van Eerd; I Agache; I J Ansotegui; M Bewick; T Casale; M Dykewick; M Ebisawa; R Murray; R Naclerio; Y Okamoto; D V Wallace Journal: Clin Transl Allergy Date: 2019-03-11 Impact factor: 5.871
Authors: P W Hellings; B Pugin; G Mariën; C Bachert; C Breynaert; D M Bullens; J L Ceuppens; G Clement; T Cox; D Ebo; P Gevaert; S Halewyck; V Hox; K Ladha; R Jacobs; P Rombaux; R Schrijvers; K Speleman; X Van der Brempt; L Van Gerven; O Vanderveken; B Verhaeghe; K Vierstraete; S Vlaminck; J-B Watelet; J Bousquet; S F Seys Journal: Clin Transl Allergy Date: 2019-02-04 Impact factor: 5.871
Authors: J Bousquet; S Arnavielhe; A Bedbrook; M Bewick; D Laune; E Mathieu-Dupas; R Murray; G L Onorato; J L Pépin; R Picard; F Portejoie; E Costa; J Fonseca; O Lourenço; M Morais-Almeida; A Todo-Bom; A A Cruz; J da Silva; F S Serpa; M Illario; E Menditto; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; D Larenas-Linnemann; M Fuentes Perez; Y R Huerta Villabolos; D Rivero-Yeverino; E Rodriguez-Zagal; F Amat; I Annesi-Maesano; I Bosse; P Demoly; P Devillier; J F Fontaine; J Just; T P Kuna; B Samolinski; A Valiulis; R Emuzyte; V Kvedariene; D Ryan; A Sheikh; P Schmidt-Grendelmeier; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P Tomazic; W J Fokkens; N H Chavannes; S Reitsma; J M Anto; V Cardona; T Dedeu; J Mullol; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; B Gemicioğlu; A Yorgancioglu; N Papadopoulos; E P Prokopakis; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; E Zernotti; I Kull; E Melen; M Wickman; C Bachert; P Hellings; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; M Sova; G De Vries; M van Eerd; I Agache; T Casale; M Dykewickz; R N Naclerio; Y Okamoto; D V Wallace Journal: Clin Transl Allergy Date: 2018-10-25 Impact factor: 5.871